Royalty Pharma plc announced that it has entered into an agreement with Merck, known as MSD outside of the United States and Canada, to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor currently being evaluated in a Phase 2b study for the treatment of schizophrenia.